In a strategic move poised to further disrupt the Ayurvedic wellness sector, fast-emerging D2C brand Dr. Mantra has secured a crucial round of bridge funding from Deep Bajaj and Mohit Bajaj, the entrepreneurial minds behind the renowned FemTech brand, Sirona. This investment marks a significant milestone for Dr. Mantra as it prepares to scale its operations and gear up for its Series A funding round.
The infused new capital shall be used for scaling up current business operations of the brand by two-fold. This growth plan marks the beginning of the upcoming Series A funding round for Dr. Mantra, with the company already in talks with several potential investors. A number of committed plans toward expansion, quite aggressive in nature, clearly express the commitment and drive to make it one of Ayurveda wellness leaders.
Founded in 2021 by Takki Zain and Shivansh Jain, Dr. Mantra was born out of a desire to address pressing health issues, particularly focusing on the treatment of kidney stones. The brand’s distinct approach lies in its ability to blend the time-honored principles of Ayurveda with modern medical practices, resulting in highly effective wellness solutions that resonate with contemporary consumers.
Dr. Mantra has quickly gained recognition for its innovative Ayurvedic treatments, particularly in the area of kidney stone management, positively impacting over 20,000 lives in just two and a half years. The brand’s rapid growth is evident in its financial performance, with revenue tripling in the past six months and maintaining a strong Rs 60 lakhs MRR, all while ensuring positive unit economics. This latest funding round follows an earlier investment of Rs 1.25 crore from 100X.VC’s Sanjay Mehta and his team.